Overview

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of colorectal cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Gilead Sciences
Immunomedics, Inc.
Treatments:
Labetuzumab